Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: A meta-analysis

European Journal of Internal Medicine

Volumn 25, Issue 5, 2014, Pages 491-495

  Liu, Yun ^a   Shi, Hongyang ^a   Sun, Xiuzhen ^a   Zhang, Dexin ^a   Zhang, Yuping ^a   Yang, Kunzheng ^b   Mi, Liehan ^c   Li, Manxiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Xi'an North Hospital   (China)

^c Traditional Chinese Medicine Hospital of Shaan Xi Province   (China)

Author keywords

COPD; Efficacy; Fluticasone propionate salmeterol; Meta analysis; Safety; Tiotropium

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; META ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; DISEASE COURSE; DRUG COMBINATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ALBUTEROL; ANDROSTADIENES; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84901609241     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.04.007     Document Type: Article

References (21)

1. K.R. Chapman, D.M. Mannino, J.B. Soriano, P.A. Vermeire, A.S. Buist, and M.J. Thun et al. Epidemiology and costs of chronic obstructive pulmonary disease Eur Respir J 27 2006 188 207
2. J.C. Hogg, F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, and L. Buzatu et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653
3. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, and A. Anzueto et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
4. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
5. N.C. Barnes, Y.S. Qiu, I.D. Pavord, D. Parker, P.A. Davis, and J. Zhu et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease Am J Respir Crit Care Med 173 2006 736 743
6. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
7. G.T. Ferguson, A. Anzueto, R. Fei, A. Emmett, K. Knobil, and C. Kalberg Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Respir Med 102 2008 1099 1108
8. E.J. Welsh, C.J. Cates, and P. Poole Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease Cochrane Database Syst Rev 5 2013 CD007891
9. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 [W64]
10. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbe Incorporating variations in the quality of individual randomized trials into meta-analysis J Clin Epidemiol 45 1992 255 265
11. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, and R. Goldstein et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 146 2007 545 555
12. M. Cazzola, F. Ando, P. Santus, P. Ruggeri, F. Di Marco, and A. Sanduzzi et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD Pulm Pharmacol Ther 20 2007 556 561
13. L.Z. Fang, X. Liang, J.Q. Zhang, L. Liu, W.P. Fu, and Z.H. Zhao et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Zhonghua Jie He He Hu Xi Za Zhi 31 2008 811 814
14. N.A. Hanania, G.D. Crater, A.N. Morris, A.H. Emmett, D.M. O'Dell, and D.E. Niewoehner Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD Respir Med 106 2012 91 101
15. M. Hoshino, and J. Ohtawa Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease Respirology 16 2011 95 101
16. K.S. Jung, H.Y. Park, S.Y. Park, S.K. Kim, Y.K. Kim, and J.J. Shim et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study Respir Med 106 2012 382 389
17. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, P.G. San, and R.L. ZuWallack et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224
18. D.E. Niewoehner, K. Rice, C. Cote, D. Paulson, J.A. Cooper Jr., and L. Korducki et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial Ann Intern Med 143 2005 317 326
19. D.A. Mahler, P. Wire, D. Horstman, C.N. Chang, J. Yates, and T. Fischer et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 2002 1084 1091
20. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, and A. Gulsvik et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
21. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, and J.P. Ioannidis et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94